High-capacity adenoviral vectors for gene transfer and somatic gene therapy

Human Gene Therapy

Volumn 10, Issue 15, 1999, Pages 2451-2459

  Kochanek, Stefan ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HELPER CELL; IMMUNOGENICITY; NONHUMAN; PATHOGENESIS; PROMOTER REGION; REVIEW; VIRUS GENE;

ADENOVIRIDAE; CYTOTOXICITY, IMMUNOLOGIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0033543992     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016807     Document Type: Review

References (65)

1. ALEMANY, R., DAI, Y., LOU, Y.C., SETHI, E., PROKOPENKO, E., JOSEPHS, S.F., and ZHANG, W.-W. (1997). Complementation of helper-dependent adenoviral vectors: Size effects and titer fluctuations. J. Virol. Methods 68, 147-159.
2. BERKNER, K.L. (1988). Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 6, 616-629.
3. BURCIN, M.M., SCHIEDNER, G., KOCHANEK, S., TSAI, S.Y., and O'MALLEY, B.W. (1999). Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. U.S.A. 96, 355-360.
4. CHEN, H.-H., MACK, L.M., KELLY, R., ONTELL, M., KOCHANEK, S., and CLEMENS, P.R. (1997). Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. U.S.A. 94, 1645-1650.
5. CHEN, H.-H., MACK, L.M., CHOI, S.Y., ONTELL, M., KOCHANEK, S., and CLEMENS, P.R. (1999). DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum. Gene Ther. 10, 365-373.
6. CHEN, L., ANTON, M., and GRAHAM, F.L. (1996). Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat. Cell. Mol. Genet. 22, 477-488.
7. CLEMENS, P.R., KOCHANEK, S., SUNADA, Y., CHAN, S., CHEN, H.-H., CAMPBELL, K.P., and CASKEY, C.T. (1996). In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3, 965-972.
8. DAI, Y., SCHWARZ, E.M., GU, D., ZHANG, W.-W., SARVETNICK, N., and VERMA, I.M. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. U.S.A. 92, 1401-1405.
9. DANIELL, E. (1976). Genome structure of incomplete particles of adenovirus. J. Virol. 19, 685-708.
10. DEURING, R., KLOTZ, G., and DOERFLER, W. (1981). An unusual symmetric recombinant between adenovirus type 12 DNA and human cell DNA. Proc. Natl. Acad. Sci. U.S.A. 78, 3142-3146.
11. FALLAUX, F.J., BOUT, A., VAN DER VELDE, I., VAN DEN WOLLENBERG, D.J., HEHIR, K.M., KEEGAN, J., AUGER, C., CRAMER, S.J., VAN ORMONDT, H., VAN DER EB, A.J., VALERIO, D., and HOEBEN, R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909-1917.
12. FELDMAN, L.T., IMPERIALE, M.J., and NEVINS, J.R. (1982). Activation of early adenovirus transcription by the herpesvirus immediate early gene: Evidence for a common cellular control factor. Proc. Natl. Acad. Sci. U.S.A. 79, 4952-4956.
13. FENG, M., JACKSON, W.H., JR., GOLDMAN, C.K., RANCOURT, C., WANG, M., DUSING, S.K., SIEGAL, G., and CURIEL, D.T. (1997). Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotechnol. 15, 866-870.
14. FISHER, K.J., CHOI, H., BURDA, J., CHEN, S.-J., and WILSON, J.M. (1996). Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217, 11-22.
15. GAO, G.-P., YANG, Y., and WILSON, J.M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70, 8934-8943.
16. GLUZMAN, Y., and VAN DOREN, K. (1983). Palindromic adenovirus type 5-simian virus 40 hybrid. J. Virol. 45, 91-103.
17. GRAEBLE, M., and HEARING, P. (1990). Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant. J. Virol. 64, 2047-2056.
18. GRAEBLE, M., and HEARING, P. (1992). cis and trans requirements for the selective packaging of adenovirus type 5 DNA. J. Virol. 66, 723-731.
19. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
20. HAECKER, S.E., STEDMAN, H.H., BALICE-GORDON, R.J., SMITH, D.B., GREELISH, J.P., MITCHELL, M.A., WELLS, A., SWEENEY, H.L., and WILSON, J.M. (1996). In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum. Gene Ther. 7, 1907-1914.
21. HAMMARSKJOLD, M.-L., and WINBERG, G. (1980). Encapsidation of adenovirus 16 DNA is directed by a small DNA sequence at the left end of the genome. Cell 20, 787-795.
22. HARDY, S., KITAMURA, M., HARRIS-STANSIL, T., DAI, Y., and PHIPPS, M.L. (1997). Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71, 1842-1849.
23. HARTLEY, J.W., HEUBNER, R.J., and ROWE, W.P. (1956). Serial propagation of adenoviruses (APC) in monkey kidney tissue cultures. Proc. Soc. Exp. Biol. Med. 92, 667.
24. HARUI, A., SUZUKI, S., KOCHANEK, S., and MITANI, K. (1999). Stable integration of adenoviral vectors into host chromosomes. J. Virol. 73, 6141-6146.
25. HASSELL, J.A., LUKANIDIN, E., FEY, G., and SAMBROOK, J. (1978). The structure and expression of two defective adenovirus 2/simian virus 40 hybrids. J. Mol. Biol. 120, 209-247.
26. HEARING, P., SAMULSKI, R.J., WISHART, W.L., and SHENK, T. (1987). Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome. J. Virol. 61, 2555-2558.
27. IMPERIALE, M.J., KAO, H.-T., FELDMAN, L.T., NEVINS, J.R., and STRICKLAND, S. (1984). Common control of the heat shock gene and early adenovirus genes: Evidence for a cellular E1A-like activity. Mol. Cell. Biol. 4, 867-874.
28. JOOSS, K., YANG, Y., FISHER, K.J., and WILSON, J.M. (1998). Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72, 4212-4223.
29. KAPLAN, J.M., ST. GEORGE, J.A., PENNINGTON, S.E., KEYES, L.D., JOHNSON, R.P., WADSWORTH, S.C., and SMITH, A.E. (1996). Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther. 3, 117-127.
30. KLESSIG, D.F. (1984). Adenovirus-simian virus 40 interactions. In The Adenoviruses. H.S. Ginsberg, ed. (Plenum Press, New York).
31. KOCHANEK, S., CLEMENS, P.R., MITANI, K., CHEN, H.-H., CHAN, S., and CASKEY, C.T. (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. U.S.A. 93, 5731-5736.
32. KOZARSKY, K.F., McKINLEY, D.R., AUSTIN, L.L., RAPER, S.E., STRATFORD-PERRICAUDET, L.D., and WILSON, J.M. (1994). In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. 269, 13695-13702.
33. KRASNYKH, V., DMITRIEV, I., MIKHEEVA, G., MILLER, C.R., BELOUSOVA, N., and CURIEL, D.T. (1998). Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 72, 1844-1852.
34. KUMAR-SINGH, R., and CHAMBERLAIN, J.S. (1996). Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. 5, 913-921.
35. KUMAR-SINGH, R., and FARBER, D.B. (1998). Encapsidated adenovirus minichromosome-mediated delivery of genes to the retina: Application to the rescue of photoreceptor degeneration. Hum. Mol. Genet. 7, 1893-1900.
36. LEWIS, A.M., JR., and ROWE, W.P. (1970). Isolation of two plaque variants from the adenovirus type 2-simian virus 40 hybrid population which differ in their efficiency in yielding simian virus 40. J. Virol. 5, 413-420.
37. LEWIS, A.M., JR., BAUM, S.G., PRIGGE, K.O., and ROWE, W.P. (1966). Occurrence of adenovirus-SV40 hybrids among monkey kidney cell adapted strains of adenovirus. Proc. Soc. Exp. Biol. Med. 122, 214-218.
38. LIEBER, A., HE, C.Y., KIRILLOVA, I., and KAY, M.A. (1996). Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70, 8944-8960.
39. LIEBER, A., HE, C.-Y., and KAY, M.A. (1997a). Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nature Biotechnol. 15, 1383-1387.
40. LIEBER, A., HE, C.Y., MEUSE, L., SCHOWALTER, D., KIRILLOVA, I., WINTHER, B., and KAY, M.A. (1997b). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71, 8798-8807.
41. LUSKY, M., CHRIST, M., RITTNER, K., DIETERLE, A., DREYER, D., MOUROT, B., SCHULTZ, H., STOECKEL, F., PAVIRANI, A., and MEHTALI, M. (1998). In vitro and in vivo biology of recombinant adenovirus vectors with El, E1/E2A or E1/E4 deleted. J. Virol. 72, 2022-2032.
42. MANSOUR, S.L., GRODZICKER, T., and TJIAN, R. (1985). An adenovirus vector system used to express polyoma virus tumor antigens. Proc. Natl. Acad. Sci. U.S.A. 82, 1359-1363.
43. MICHOU, A.I., SANTORO, L., CHRIST, M., JULLIARD, V., PAVIRANI, A., and MEHTALI, M. (1997). Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther. 4, 473-482.
44. MITANI, K., GRAHAM, F.L., CASKEY, C.T., and KOCHANEK, S. (1995). Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc. Natl. Acad. Sci. U.S.A. 92, 3854-3858.
45. MORRAL, N., O'NEAL, W., ZHOU, H., LANGSTON, C., and BEAUDET, A. (1997). Immune response to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors. Hum. Gene Ther. 8, 1275-1286.
46. 1-antitrypsin with negligible toxicity. Hum. Gene Ther. 9, 2709-2716.
47. MORSY, M.A., GU, M., MOTZEL, S., ZHAO, J., LIN, J., SU, Q., ALLEN, H., FRANLIN, L., PARKS, R.J., GRAHAM, F.L., KOCHANEK, S., BETT, A.J., and CASKEY, C.T. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U.S.A. 95, 7866-7871.
48. MURUVE, D.A., BARNES, M.J., STILLMAN, I.E., and LIBERMANN, T.A. (1999). Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10, 965-976.
49. PARKS, R.J., and GRAHAM, F.L. (1997). A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J. Virol. 71, 3293-3298.
50. PARKS, R.J., CHEN, L., ANTON, M., SANKAR, U., RUDNICKI, M.A., and GRAHAM, F.L. (1996). A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93, 13565-13570.
51. PIERCE, W.E., ROSENBAUM, M.J., EDWARDS, E.A., PECKINPAUGH, R.O., and JACKSON, G.G. (1968). Live and inactivated adenovirus vaccines for the prevention of acute respiratory illness in naval recruits. Am. J. Epidemiol. 87, 237-246.
52. RECCHIA, A., PARKS, R.J., LAMARTINA, S., TONIATTI, C., PIERONI, L., PALOMBO, F., CILIBERTO, G., GRAHAM, F.L., CORTESE, R., LA MONICA, N., and COLLOCA, S. (1999). Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc. Natl. Acad. Sci. U.S.A. 96, 2615-2620.
53. SAUER, B. (1987). Functional expression of the Cre-lox site-specific recombination system in the yeast Saccharomyces cerevisiue. Mol. Cell. Biol. 7, 2087-2096.
54. SCHIEDNER, G., MORRAL, N., PARKS, R.J., WU, Y., KOOPMANS, S.C., LANGSTON, C., GRAHAM, F.L., BEAUDET, A.L., and KOCHANEK, S. (1998). A high-capacity adenovirus vector with all viral genes deleted results in improved in vivo gene expression and decreased toxicity. Nature Genet. 18, 180-183.
55. SYKES, R.C., LIN, D., HWANG, S.J., FRAMSON, P.E., and CHINAULT, A.C. (1988). Yeast ARS function and nuclear matrix association coincide in a short sequence from the human HPRT locus. Mol. Gen. Genet. 212, 301-309.
56. TIBBETTS, C. (1977). Viral DNA sequences from incomplete particles of human adenovirus type 7. Cell 12, 243-249.
57. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2, 545-550.
58. VAN GINKEL, F.W., LIU, C., SIMECKA, J.W., DONG, J.-Y., GREENWAY, T., FRIZZELL, R.A., KIYONO, H., McGHEE, J.R., and PASCUAL, D.W. (1995). Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum. Gene Ther. 6, 895-903.
59. WADSWORTH, S.C., ZHOU, H., SMITH, A.E., and KAPLAN, J.M. (1997). Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J. Virol. 71, 5189-5196.
60. WANG, Q., GREENBURG, G., BUNCH, D., PARSON, D., and FINER, M.H. (1997). Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Gene Ther. 4, 393-400.
61. WERSTO, R.P., ROSENTHAL, E.R., SETH, P.K., EISSA, N.T., and DONAHUE, R.E. (1998). Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins. J. Virol. 72, 9491-9502.
62. WICKHAM, T.J., TZENG, E., SHEARS, L.L., II, ROELVINK, P.W., LI, Y., LEE, G.M., BROUGH, D.E., LIZONOVA, A., and KOVESDI, I. (1997). Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71, 8221-8229.
63. YAMADA, M., LEWIS, J.A., and GRODZICKER, T. (1985). Overproduction of the protein product of a nonselected foreign gene carried by an adenovirus vector. Proc. Natl. Acad. Sci. U.S.A. 82, 3567-3571.
64. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GONCZOL, E., and WILSON, J.M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
65. YANG, Y., LI, Q., ERTL, H.C.J., and WILSON, J.M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenviruses. J. Virol. 69, 2004-2015.